

CITATION REPORT

List of articles citing

HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy

DOI: 10.1182/blood-2013-12-545087
Blood, 2014, 123, 2924-33.

Source: <https://exaly.com/paper-pdf/58949266/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
241	Castleman's disease of the mesocolon: a rare case report. 2014 , 1,		
240	Castleman Disease. A Report of Six Cases. 2014 , 87, 192-7		3
239	Retroperitoneal unicentric Castleman's disease-a hyaline vascular challenge. 2014 , 18, 1878-80		2
238	Siltuximab for multicentric Castleman disease. 2014 , 7, 545-57		13
237	Exploiting interleukin 6 in multicentric Castleman's disease. 2014 , 15, 910-2		9
236	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. 2014 , 15, 966-74		259
235	Siltuximab: first global approval. 2014 , 74, 1147-52		22
234	Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. <i>Blood</i> , 2014 , 124, 3544-52	2.2	67
233	Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. 2015 , 3, 472-8		31
232	Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2. 2015 , 236, 289-95		37
231	[Multicentric Castleman's disease characterized by polyclonal hyperimmunoglobulinemia and paraneoplastic pemphigus]. 2015 , 72, 129-139		
230	Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. <i>British Journal of Haematology</i> , 2015 , 168, 82-93	4.5	9
229	Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. <i>British Journal of Haematology</i> , 2015 , 169, 834-42	4.5	43
228	Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. 2015 , 39, 132-9		88
227	Clinical development of siltuximab. 2015 , 17, 29		6
226	CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. 2015 , 8, 343-54		22
225	Interleukin-6 as a therapeutic target. 2015 , 21, 1248-57		218

224	Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. 2015 , 8, 207-16	15
223	Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report. 2015 , 15, 4	2
222	Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease. 2015 , 94, 1241-3	4
221	Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. 2015 , 29, 399-406	2
220	[Asthenia, weight loss and abdominal pain in a 64-year-old woman]. 2015 , 36, 706-9	
219	Update and new approaches in the treatment of Castleman disease. 2016 , 7, 145-58	59
218	Emerging treatments in Castleman disease - a critical appraisal of siltuximab. 2016 , 10, 9-15	3
217	TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature. 2016 , 2016, 4703608	19
216	Co-infections and Pathogenesis of KSHV-Associated Malignancies. 2016 , 7, 151	26
215	Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor. 2016 , 6, 23831	14
214	Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge. 2017 , 56, 665-668	1
213	An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy. 2016 , 4, e00173	14
212	Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. 2016 , 95, e5047	3
211	Un syndrome de Schnitzler r��p�� par une maladie de Castleman : cas clinique et description histologique. 2016 , 37, A134-A135	
210	Multicentric Castleman disease: Where are we now?. 2016 , 33, 294-306	61
209	Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. 2016 , 40, 495-501	27
208	Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. 2016 , 103, 686-92	125
207	Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. 2016 , 91, 220-6	153

206	Castleman Disease of the Thorax: Clinical, Radiologic, and Pathologic Correlation: From the Radiologic Pathology Archives. 2016 , 36, 1309-32	28
205	Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. 2016 , 18, 167	104
204	Lung Disease in Primary Antibody Deficiencies. 2016 , 4, 1039-1052	42
203	IgG4-Related Kidney Disease. 2016 ,	1
202	Review of siltuximab in the treatment of multicentric Castleman's disease. 2016 , 7, 360-366	29
201	A case of TAFRO syndrome with a large mediastinal mass treated with debulking surgery. 2016 , 2, 61	7
200	Clinical spectrum of Castleman disease-associated neuropathy. 2016 , 87, 2457-2462	25
199	TAFRO syndrome with primary Sjogren's syndrome. 2016 , 39, 478-484	7
198	TAFRO syndrome with a rapid fatal course despite corticosteroid and tocilizumab therapy. 2016 , 9, 167-171	1
197	Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan--two case studies. 2016 , 96, 541-3	4
196	TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease. 2016 , 91, 171-2	15
195	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. 2016 , 8, 17-26	18
194	Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. 2016 , 103, 718-23	35
193	Idiopathic multicentric Castleman's disease: a systematic literature review. 2016 , 3, e163-75	152
192	The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. 2016 , 3, e150-2	30
191	Current diagnosis and treatment of Castleman's disease. 2016 , 216, 146-156	
190	Autoimmune and Lymphoproliferative Complications of Common Variable Immunodeficiency. 2016 , 16, 19	42
189	Current diagnosis and treatment of Castleman's disease. 2016 , 216, 146-56	7

188	TAFRO syndrome: 2 cases and review of the literature. 2017 , 27, 1093-1097		24
187	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017 , 129, 1646-1657	2.2	234
186	Case 6-2017. A 57-year-old woman with fatigue, sweats, weight loss, headache, and skin lesions. 2017 , 376, 775-786		5
185	Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease. 2017 , 70, 1114-1124		24
184	Elevated serum interferon β -induced protein 10 kDa is associated with TAFRO syndrome. 2017 , 7, 42316		36
183	JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. 2017 , 153, 449-452		7
182	Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. <i>Blood</i> , 2017 , 129, 1658-1668	2.2	88
181	Human herpesvirus 8-related diseases: Histopathologic diagnosis and disease mechanisms. 2017 , 34, 371-376		7
180	TAFRO syndrome: A case report and review of the literature. 2017 , 10, 1-4		3
179	Unraveling Castleman: progress in a complex process. <i>Blood</i> , 2017 , 129, 1570	2.2	1
178	Multicentric Castleman disease: consensus at last?. <i>Blood</i> , 2017 , 129, 1569-1570	2.2	1
177	Castleman disease-associated diffuse parenchymal lung disease: A STROBE-compliant retrospective observational analysis of 22 cases in a tertiary Chinese hospital. 2017 , 96, e8173		11
176	A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. 2017 , 213, 1378-1383		3
175	A Large Retroperitoneal Mass in an Asymptomatic 22-Year-Old Man. 2017 , 153, 1200-1202		
174	Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab. 2017 , 96, 2117-2119		11
173	Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease. 2017 , 3, e000432		25
172	Une anasarque fébrile n'est pas un syndrome TAFRO. 2017 , 38, A224		
171	An Incidental Hypervascular Retroperitoneal Mass. 2017 , 152, 887-888		0

170	Therapeutic outlook for Castleman's disease: prospects for the next decade. 2017 , 5, 633-640			1
169	A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America. 2017 , 96, e6271			26
168	Castleman's disease of the spleen. 2017 , 117, 203-208			5
167	Biology and Management of Unusual Plasma Cell Dyscrasias. 2017 ,			
166	POEMS Syndrome and Castleman's Disease. 2017 , 41-69			2
165	Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report. 2017 , 96, e9220			8
164	Anasarca, Fever, Thrombocytopenia, Organomegaly, and Multiorgan Failure in a 24-Year-Old Pregnant Woman. 2017 , 2017, 3871593			2
163	Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder. 2017 , 2017, 5235163			
162	Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions. <i>Internal Medicine</i> , 2017 , 56, 1095-1099		1.1	10
161	TAFRO Syndrome: A Novel Systemic Inflammatory Disorder Characterized by Thrombocytopenia, Anasarca, Fever, Renal Dysfunction and Organomegaly. 2017 , 07,			
160	Leveraging information and collaboration to cure disease. 2017 , 37, 307-311			
159	TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. 2017 , 17, 81-84			16
158	TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review. 2018 , 28, 564-569			26
157	TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. 2018 , 7, 162-168			16
156	Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. 2018 , 93, 902-912			33
155	The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. 2018 , 77, 130-138			7
154	Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements. 2018 , 6, 644-650			8
153	A case of TAFRO syndrome successfully treated with cyclosporin A and tocilizumab. <i>Modern Rheumatology Case Reports</i> , 2018 , 2, 209-213			0.4

152	Epidemiology of Castleman Disease. 2018 , 32, 1-10		36
151	Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. 2018 , 109, 199-206		30
150	Severe refractory TAFRO syndrome requiring continuous renal replacement therapy complicated with infection in the lungs and myocardial infarction: an autopsy case report and literature review. 2018 , 4, 16		0
149	A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment. 2018 , 19, 949-952		1
148	Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. 2018 , 28, 161-167		21
147	Treatment of Idiopathic Castleman Disease. 2018 , 32, 89-106		29
146	Clinical, laboratory and imaging findings in Castleman's disease - The subtype decides. 2018 , 32, 225-234		15
145	Castleman Disease Pathogenesis. 2018 , 32, 11-21		43
144	Pathology of Castleman Disease. 2018 , 32, 37-52		45
143	TAFRO Syndrome. 2018 , 32, 107-118		24
142	The full spectrum of Castleman disease: 273 patients studied over 20 years. <i>British Journal of Haematology</i> , 2018 , 180, 206-216	4.5	71
141	Castleman disease: delineating the spectrum. <i>British Journal of Haematology</i> , 2018 , 180, 173-174	4.5	
140	Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report. 2018 , 57, 703-705		3
139	Do you know TAFRO?. <i>Blood</i> , 2018 , 132, 2109-2110	2.2	1
138	Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. <i>Blood</i> , 2018 , 132, 2323-2330	2.2	47
137	TAFRO syndrome complicated with occlusion of multiple cerebral arteries. <i>Modern Rheumatology Case Reports</i> , 2018 , 2, 214-220	0.4	1
136	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018 , 132, 2115-2124	2.2	127
135	A novel mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. 2018 , 2, 2959-2963		8

134	Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. 2018 , 2018, 318-325	5
133	Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. 2018 , 2, 481-491	27
132	Possible Association of Multicentric Castleman's Disease with Autoimmune Lymphoproliferative Syndrome. 2018 , 7, 47-51	3
131	TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin. <i>Internal Medicine</i> , 2018 , 57, 1291-1296	1.1 10
130	Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. 2018 , 2018, 5895903	
129	Reactive Lymph Nodes and Castleman Disease. 2018 , 118-166.e5	
128	Pathologies rares pouvant simuler un lupus. 2018 , 85, 245-252	
127	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. 2018 , 97, 1641-1647	7
126	Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately. 2018 , 144, 1265-1277	2
125	Recurrence in unicentric castleman's disease postoperatively: a case report and literature review. 2018 , 18, 1	16
124	TAFRO syndrome: current perspectives. 2018 , 9, 15-23	15
123	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. 2018 , 36, 689-692	4
122	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. 2018 , 66, 83-86	6
121	Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review. 2018 , 97, e11045	16
120	Tafro syndrome: Critical review for clinicians and pathologists. 2018 , 128, 88-95	9
119	The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome. 2019 , 215, 152563	2
118	Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era. 2019 , 14, 173	1
117	Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital. 2019 , 60, 3442-3448	4

116	Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. 2019 , 14, e0218660		10
115	Hepatic <i>Campylobacter jejuni</i> infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome). <i>Pathology International</i> , 2019 , 69, 572-579	1.8	2
114	Constipation With a Palpable Abdominal Mass in a Young Woman. 2019 , 157, e12-e13		1
113	Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. 2019 , 66, e27613		11
112	Storming the Castle with TCP. <i>Blood</i> , 2019 , 133, 1697-1698	2.2	1
111	Context-specific tumor suppression by PHF6. <i>Blood</i> , 2019 , 133, 1698-1700	2.2	1
110	Multicentric Castleman disease with TAFRO syndrome and Sjögren's. 2019 , 7, 2388-2392		5
109	Polyneuropathy, organomegaly, endocrinopathy, monoclonal band, and skin (POEMS) changes syndrome presenting with a pseudosensory level: a case report. 2019 , 13, 384		1
108	Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report. 2019 , 98, e17681		4
107	Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. <i>British Journal of Haematology</i> , 2019 , 184, 232-241	4.5	21
106	Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). 2019 , 86, 165-171		18
105	Recurrent PDGFRB mutations in unicentric Castleman disease. 2019 , 33, 1035-1038		21
104	An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. 2019 , 215, 410-413		8
103	A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. 2019 , 29, 302-305		8
102	Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study. 2020 , 50, 184-191		8
101	An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone. 2020 , 20, 84-86		1
100	Periodic and Non-Periodic Fevers. <i>Rare Diseases of the Immune System</i> , 2020 ,	0.2	
99	Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease. <i>British Journal of Haematology</i> , 2020 , 188, e64-e67	4.5	4

98	A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. 2020 , 25, 963-973		4
97	Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. <i>BMC Nephrology</i> , 2020 , 21, 499	2.7	5
96	FDG PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings. 2020 , 10,		3
95	Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial. 2020 , 99, e20710		5
94	Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease. 2020 , 10,		4
93	Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab. 2020 , 13,		6
92	Predominant Stroma-Rich Feature in Hyaline Vascular Variant of Castleman Disease Is Associated With Paraneoplastic Pemphigus. 2020 , 154, 403-413		1
91	Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. 2020 , 413, 116771		3
90	AA amyloidosis associated with Castleman disease: A case report and review of the literature. 2020 , 99, e18978		0
89	Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population. 2020 , 153, 821-832		2
88	Multicentric Castleman's disease in a renal allograft recipient: a case report and literature review. 2020 , 48, 300060519897481		1
87	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. 2020 , 7, e209-e217		17
86	Idiopathic multicentric Castleman disease: bringing order to chaos. 2020 , 7, e180-e181		
85	Unicentric Castleman disease and lymphoepithelial cyst of the parotid: A case report and review of the literature. 2020 , 17, 106-110		
84	Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. 2020 , 146, 357-365		4
83	A Rare Presentation of Orbital Castleman's Disease. 2020 , 2020, 1012759		1
82	Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. 2021 , 26, 4-6		1
81	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. <i>British Journal of Haematology</i> , 2021 , 192, e28-e31	4.5	2

80	'Peeling back the onion layers': the challenge of HIV-associated multicentric Castleman's disease. 2021 , 35, 159-161		
79	UCD with MCD-like inflammatory state: surgical excision is highly effective. 2021 , 5, 122-128		1
78	Fatal case of TAFRO syndrome with unilateral adrenal hemorrhage in early-stage disease. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021 , 61, 109-113	1.9	0
77	Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases. 2021 , 147, 2107-2115		2
76	Histopathologic findings of TAFRO syndrome with immunohistochemical analysis of the kidney specimen: A case report. 2021 , 23, 200471		
75	The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. 2021 , 36, 424-432		3
74	Morbus Castleman Ein seltenes, heterogenes Krankheitsbild. 2021 , 16, 198-206		
73	Emerging role of 18F-FDG PET/CT in Castleman disease: a review. 2021 , 12, 35		7
72	Rare Diseases of the Orbit. 2021 , 100, S1-S79		2
71	TAFRO syndrome mimicking systemic lupus erythematosus: Case report and literature review. 2021 , ,		1
70	Complete Resolution of a Case of TAFRO Syndrome Accompanied by Mediastinal Panniculitis, Adrenal Lesion, and Liver Damage with Hyperbilirubinemia. <i>Internal Medicine</i> , 2021 , 60, 1303-1309	1.1	0
69	Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report. 2021 , 100, e25961		0
68	[Multicentric Castleman's disease combined with polyserositis and POEMS syndrome: case report and review article]. 2021 , 62, 777-785		0
67	Role of 18F-FDG PET/CT in the Management of Patients Affected by HHV-8-Associated Multicentric Castleman's Disease. 2021 , 2, 383-391		1
66	TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities. 2021 , 22,		0
65	Perigastric Hyaline-Vascular Variant Castleman's Disease. 2021 , 15, 632-638		0
64	IgG4-related disease and idiopathic multicentric Castleman's disease: confusable immune-mediated disorders. 2021 ,		1
63	Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab. 2021 , 57,		0

62	Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease. 2021 , 1		
61	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. 2021 , 107, 642-649		1
60	TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy. 2021 , 14, 1359-1365		0
59	A retrospective study of 44 patients with head and neck Castleman's disease. 2021 , 1		1
58	KSHV/HHV8-mediated hematologic diseases. <i>Blood</i> , 2021 ,	2.2	3
57	Updates on the diagnosis and management of multicentric Castleman disease. 2021 , 33, 22-28		2
56	Encyclopedia of Pathology. <i>Encyclopedia of Pathology</i> , 2018 , 1-7	0	1
55	Computed tomography findings of early-stage TAFRO syndrome and associated adrenal abnormalities. 2020 , 30, 5588-5598		5
54	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. 2020 , 1, 100158		5
53	The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. 2019 , 3, 97-105		3
52	Castleman's disease in carcinoma gall bladder. 2016 , 2016,		1
51	Unicentric Castleman's disease presenting as a pulmonary mass: a diagnostic dilemma. 2015 , 16, 259-61		8
50	Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease. 2018 , 9, 6691-6706		21
49	In silico Insights on IL-6: A Potential Target for Multicentric Castleman Disease. 2020 , 16, 641-653		7
48	Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare Coexistence. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2015 , 55, 103-8	1.9	1
47	Transcriptome and unique cytokine microenvironment of Castleman disease. 2021 ,		0
46	Multicentric Castleman Disease Mimicking IgG4-Related Disease: A Case Report. 2016 , 293-301		
45	Differential Diagnosis (2): Castleman Disease. 2016 , 261-269		

44	A patient with Castleman's disease mimicking acute pancreatitis. 2017 , 109, 737-738		
43	Idiopathic Multicentric Castleman's Disease with Normal Interleukin-6 Levels. 2018 , 6,		
42	A case report of TAFRO (thrombocytopenia, ascites, fever, renal dysfunction, organomegaly) syndrome with suspicion of tocilizumab removal by plasma exchange. 2018 , 25, 211-212		
41	Herpesvirus-assoziierte lymphoproliferative Erkrankungen und maligne Lymphome. 2019 , 717-792		
40	Tumorartige Lymphadenopathien. 2019 , 481-493		
39	CD20-Negative Aggressive Lymphomas. <i>Mechanical Engineering Series</i> , 2019 , 213-226	0.3	
38	Last Resort. <i>Journal of Hospital Medicine</i> , 2019 , 14, E1-E5	2.7	
37	Hematopathology. <i>Encyclopedia of Pathology</i> , 2020 , 99-105	0	
36	Castleman Disease. <i>Rare Diseases of the Immune System</i> , 2020 , 215-228	0.2	
35	Human herpesvirus 8-positive multicentric Castleman disease with germinotropic plasmablastic aggregates: Overlapping spectrum of human herpesvirus 8-associated lymphoproliferative disorder. <i>Pathology International</i> , 2020 , 70, 574-580	1.8	1
34	Non-neoplastic Conditions with Quantitative and Qualitative Changes in Hematopoiesis. <i>Essentials of Diagnostic Pathology</i> , 2020 , 27-80	0	
33	Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease. <i>Internal Medicine</i> , 2020 , 59, 3061-3065	1.1	2
32	A Case of Castleman's Disease in Mesorectum Concomitant with Rectal Cancer with Simultaneous Laparoscopic Resection. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2020 , 73, 389-394	0.1	
31	Liver cirrhosis in a child associated with Castleman's disease: A case report. <i>World Journal of Clinical Cases</i> , 2020 , 8, 1656-1665	1.6	0
30	Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report. <i>World Journal of Clinical Cases</i> , 2020 , 8, 4922-4929	1.6	0
29	Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research. <i>Yale Journal of Biology and Medicine</i> , 2015 , 88, 383-8	2.4	4
28	TAFRO Syndrome: A Case Report from Turkey and Review of the Literature. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2018 , 12, 253-259	0.5	2
27	Castleman Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015 , 32, 41S-46S	0.7	

26	Castleman's disease. <i>Journal of Oral and Maxillofacial Pathology</i> , 2020 , 24, 593	1.2	
25	Castleman disease. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 84	51.1	3
24	Multizentrischer Morbus Castleman: Selten korrekt diagnostiziert.		
23	To and TAFRO - a cryptic cause of acute renal failure: a case report.. <i>BMC Nephrology</i> , 2022 , 23, 19	2.7	
22	A Patient with Castleman's Disease Initially Manifesting Symmetrical Synovitis with Pitting Edema.. <i>Modern Rheumatology Case Reports</i> , 2022 ,	0.4	
21	Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.. <i>World Journal of Clinical Cases</i> , 2022 , 10, 1536-1547	1.6	
20	A Case of TAFRO Syndrome Maintained in Remission for 5 Years After Discontinuation of Tocilizumab.. <i>Modern Rheumatology Case Reports</i> , 2022 ,	0.4	
19	A Case of TAFRO Syndrome that Responded to Prednisolone-only Treatment: Evaluating Changes in IL-6.. <i>Internal Medicine</i> , 2022 ,	1.1	0
18	Multicentric Castleman's disease. Symptoms, diagnostics and therapy. <i>Vnitřni Lekarství</i> , 2022 , 68, 41-53	0.3	
17	Benign Hematologic Disorders Involving the Liver and Spleen. 2020 , 329-341		
16	Case Report: Castleman Disease With an Associated Stromal Spindle Cell Proliferation, Mutation and p53 Expression: Clonal Origins of a Rare Disease.. <i>Frontiers in Oncology</i> , 2022 , 12, 857606	5.3	
15	Castleman's disease. 2020 , 24, 593		0
14	Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.. <i>Therapeutics and Clinical Risk Management</i> , 2022 , 18, 499-509	2.9	0
13	The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.. <i>British Journal of Haematology</i> , 2022 ,	4.5	
12	TAFRO Syndrome: A Disease Requiring Immediate Medical Attention. <i>Internal Medicine</i> , 2022 ,	1.1	1
11	A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome. <i>Turkish Journal of Haematology</i> ,	0.9	
10	Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022 , 62, 79-84	1.9	0
9	Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.		

- 8 Long-term treatment outcome of Castleman’s disease: A real-world experience. 12,
- 7 Glucocorticoids combined with tofacitinib in the treatment of Castleman’s disease: A case report. 10, 10794-10802
- 6 A rare HIV-associated hyaline vascular multicentric castleman disease with good early response to single-agent rituximab: A case from Tanzania. **2022**, 30, 300677
- 5 The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.
- 4 Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report. **2022**, 101, e32200
- 3 EpsteinBarr Virus-Positive Cutaneous and Systemic Plasmacytosis with TAFRO Syndrome-Like Symptoms Successfully Treated with Rituximab. **2023**, 59, 216
- 2 Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease. **2023**,
- 1 TAFRO syndrome mimicking systemic lupus erythematosus: Case report and literature review. **2022**, 29, 373-383